Explore more publications!

Press Releases

Autonomous Construction Equipment Market worth $9.77 billion by 2030 | MarketsandMarkets™
VisionWave Announces Execution of Definitive Agreement to Acquire a 51% Controlling Stake in Certified Aerospace Manufacturer Supporting Structural Components in Systems Publicly Known as Iron Dome and Barak 8 — Combining QSpeed™ Platform and…
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
Revolutionizing Sustainable Packaging Renewable Gable-Top Cartons Set to Reach USD 9.77 Billion by 2035
Data I/O and IAR Announce Collaboration to Simplify and Unify Security Provisioning from Embedded Design to Manufacturing
Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
New GEM 2025/2026 Global Report Finds Record Startup Activity — But Warns of Growing AI and Survival Gaps
Lantheus to Present at March 2026 Investor Conferences
ADT, Origin AI and Verisure Sign Long-Term Commercial Agreement to Scale AI-Driven Security
Menstrual Health Apps Market’s 20.28% CAGR Reflects Strong Investor Confidence in Women-Centric Innovation
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
AI in Blood Pressure Monitoring Enters Hypergrowth Phase with 30% CAGR Through 2035
Annual Accounts 2025

Annual Accounts 2025

21shares Launches Spot Sui ETF (TSUI) in the United States
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Easee achieves remarkable financial turnaround, posting £1.4m profit after £31.3m loss two years earlier
Hospitals Electronic Health Records Turn Data Into Better Decisions, Approaching $28.94 Billion by 2035
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions